Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $24.25.
Several research analysts have issued reports on ANL shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a report on Tuesday, July 14th. HC Wainwright boosted their price target on shares of Adlai Nortye from $16.00 to $20.00 and gave the company a “buy” rating in a report on Monday, April 20th. JonesTrading began coverage on shares of Adlai Nortye in a research report on Thursday, May 14th. They issued a “buy” rating and a $22.00 price target for the company. Oppenheimer initiated coverage on shares of Adlai Nortye in a research note on Thursday, May 28th. They set an “outperform” rating and a $32.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on shares of Adlai Nortye in a research note on Monday, June 22nd. They set an “overweight” rating on the stock.
Check Out Our Latest Analysis on Adlai Nortye
Institutional Trading of Adlai Nortye
Adlai Nortye Stock Performance
Shares of Adlai Nortye stock opened at $13.23 on Tuesday. The stock’s fifty day moving average price is $11.26 and its 200-day moving average price is $10.52. Adlai Nortye has a 12 month low of $0.88 and a 12 month high of $17.25.
About Adlai Nortye
Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
See Also
- Five stocks we like better than Adlai Nortye
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
